Authentification abonné
lvafmu
Accueil Tous les numéros Volume 12 / Numéro 1 (Janvier 2022) Ann. Fr. Med. Urgence, 12 1 (2022) 21-28 Références
Accès gratuit
Numéro
Ann. Fr. Med. Urgence
Volume 12, Numéro 1, Janvier 2022
Page(s) 21 - 28
Section Mise au point / Update
DOI https://doi.org/10.3166/afmu-2022-0376
Publié en ligne 8 février 2022
  • Maurer M, Magerl M, Ansotegui I, et al (2018) The International WAO/EAACI guideline for the management of hereditary angioedema — the 2017 revision and update. Allergy 73:1575–96 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Adnet F, Fain O (2016) Angioedème bradykiniques et médecine d’urgence : vers une optimisation de prise en charge. Reanimation 25:400–7 [CrossRef] [Google Scholar]
  • Zuberbier T, Aberer W, Asero R, et al (2018) The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy 73:1393–414 [CrossRef] [PubMed] [Google Scholar]
  • Soria A, Francès C (2014) Urticaria: diagnosis and treatment. Rev Med Interne 35:586–94 [CrossRef] [PubMed] [Google Scholar]
  • Grattan CEH, Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee (2007) Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 157:1116–23 [CrossRef] [PubMed] [Google Scholar]
  • Losappio L, Heffler E, Bussolino C, et al (2014) Acute urticaria presenting in the emergency room of a general hospital. Eur J Intern Med 25:147–50 [CrossRef] [PubMed] [Google Scholar]
  • Lee S, Hess EP, Lohse C, et al (2017) Trends, characteristics, and incidence of anaphylaxis in 2001–2010: a population-based study. J Allergy Clin Immunol 139:182–8 [CrossRef] [PubMed] [Google Scholar]
  • Simons FER, Ardusso LRF, Dimov V, et al (2013) World allergy organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 162:193–204 [CrossRef] [PubMed] [Google Scholar]
  • Simons FER, Ardusso LRF, Bilò MB, et al (2011) World allergy organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 127:587–93 [CrossRef] [PubMed] [Google Scholar]
  • Gloaguen A, Cesareo E, Vaux J, et al (2016) Prise en charge de l’anaphylaxie en médecine d’urgence. Recommandations de la Société́ française de médecine d’urgence (SFMU) en partenariat avec la Société́ française d’allergologie (SFA) et le Groupe francophone de réanimation et d’urgences pédiatriques (GFRUP), et le soutien de la Société pédiatrique de pneumologie et d’allergologie (SP2A). Ann Fr Med Urgence 6:342–64 [CrossRef] [Google Scholar]
  • Grunau BE, Wiens MO, Rowe BH, et al (2015) Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses. Ann Emerg Med 66:381–9 [CrossRef] [PubMed] [Google Scholar]
  • Choo KJL, Simons E, Sheikh A (2010) Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 65:1205–11 [CrossRef] [PubMed] [Google Scholar]
  • Pollack CV Jr, Romano TJ (1995) Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med 26:547–51 [CrossRef] [PubMed] [Google Scholar]
  • Zuberbier T, Iffländer J, Semmler C, Henz BM (1996) Acute urticaria:clinical aspects and therapeutic responsiveness. Acta Derm Venereol 76:295–7 [PubMed] [Google Scholar]
  • Barniol C, Dehours E, Mallet J, et al (2017) Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial. Ann Emerg Med 71:125–31 [Google Scholar]
  • Augey F, Guillot-Pouget I, Gunera-Saad N et al (2008) Impact of corticosteroid withdrawal in chronic urticaria: a prospective study of 17 patients. Ann Dermatol Venereol 135:21–5 [CrossRef] [PubMed] [Google Scholar]
  • Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M (2018) Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 13:73 [CrossRef] [PubMed] [Google Scholar]
  • Longhurst H, Cicardi M (2012) Hereditary angio-oedema. Lancet 379:474–81 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Gompel A, Bouillet L, et al (2015) Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Ann Allergy Asthma Immunol 114:499–503 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Schicketanz KH, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229–35 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692–7 [CrossRef] [PubMed] [Google Scholar]
  • Bork K, Staubach P, Eckardt AJ, Hardt J (2006) Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 101:619–27 [CrossRef] [PubMed] [Google Scholar]
  • Guichon C, Floccard B, Coppere B, et al (2011) One hypovolaemic shock… two kinin pathway abnormalities. Intensive Care Med 37:1227–8 [CrossRef] [PubMed] [Google Scholar]
  • Banerji A, Busse P, Shennak M, et al (2017) Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 376:717–28 [CrossRef] [PubMed] [Google Scholar]
  • Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, et al (2010) Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 203:131 [Google Scholar]
  • Bouillet L, Lehmann A, Gompel A, et al (2015) Hereditary angioedema treatments: recommendations from the French National Center for Angioedema. Presse Med 44:526–32 [CrossRef] [PubMed] [Google Scholar]
  • Zuraw BL, Busse PJ, White M, et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513–22 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Banerji A, Bracho F, et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–41 [CrossRef] [PubMed] [Google Scholar]
  • Otani IM, Lumry WR, Hurwitz S, et al (2017) Subcutaneous icatibant for the treatment of hereditary angioedema attacks: comparison of home self-administration with administration at a medical facility. J Allergy Clin Immunol Pract 5:442–7 [CrossRef] [PubMed] [Google Scholar]
  • Cicardi M, Zingale LC, Bergamaschini L, Agostoni A (2004) Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 164:910–3 [CrossRef] [PubMed] [Google Scholar]
  • Miller DR, Oliveria SA, Berlowitz DR, et al (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–30 [CrossRef] [PubMed] [Google Scholar]
  • Blacher J, Halimi JM, Hanon O, et al (2014) Management of hypertension in adults: the 2013 French Society of Hypertension Guidelines. Fundam Clin Pharmacol 28:1–9 [CrossRef] [PubMed] [Google Scholar]
  • Marant C, Romon I, Fosse S, et al (2008) French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab 34:38–45 [CrossRef] [PubMed] [Google Scholar]
  • Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al (1994) Myocardial infarction and coronary deaths in the world health organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90:583–612 [CrossRef] [PubMed] [Google Scholar]
  • Bluestein HM, Hoover TA, Banerji AS, et al (2009) Angiotensinconverting enzyme inhibitor-induced angioedema in a community hospital emergency department. Ann Allergy Asthma Immunol 103:502–7 [CrossRef] [PubMed] [Google Scholar]
  • Brown NJ, Byiers S, Carr D, et al (2009) Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitorassociated angioedema. Hypertension 54:516–23 [CrossRef] [PubMed] [Google Scholar]
  • Duerr M, Glander P, Diekmann F, et al (2010) Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5:703–8 [CrossRef] [PubMed] [Google Scholar]
  • Vigneron C, Lécluse A, Ronzière T, et al (2019) Angioedema associated with thrombolysis for ischemic stroke: analysis of a case-control study. J Intern Med 286:702–10 [CrossRef] [PubMed] [Google Scholar]
  • Baş M, Greve J, Stelter K, et al (2015) A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418–25 [CrossRef] [PubMed] [Google Scholar]
  • Roberts JR, Lee JJ, Marthers DA (2012) Angiotensin-converting enzyme (ACE) inhibitor angioedema: the silent epidemic. Am J Cardiol 109:774–5 [CrossRef] [PubMed] [Google Scholar]
  • Sinert R, Levy P, Bernstein JA, et al (2017) Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. J Allergy Clin Immunol Pract 5:1402–9 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Fain O, Adnet F (2017) Icatibant for ACE-inhibitor angioedema, an opportunity to treat the patients? J Allergy Clin Immunol Pract 5:1803 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Fain O (2019) Awareness is still warranted for ARBs. J Intern Med. 285:550–2 [CrossRef] [PubMed] [Google Scholar]
  • Gobert D, Bouillet L, Armengol G, et al (2020) Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment. Rev Med Interne 41:838–42 [CrossRef] [PubMed] [Google Scholar]
  • Javaud N, Fain O, Durand-Zaleski I, et al (2018) Specialist advice support for management of severe hereditary angioedema attacks: a multicenter cluster-randomized controlled trial. Ann Emerg Med 72:94–103 [Google Scholar]
  • Javaud N, Lapostolle F, Sapir D, et al (2013) The early treatment of bradykinin angioedema, a challenge for emergency medicine. Eur J Emerg Med 20:291–4 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.